Canadian star researcher Brendan Frey brandishes Deep Genomics' first AI-discovered drug
A startup harnessing AI in drug discovery has put forward its first therapeutic candidate — and it may not be who you’re thinking.
To be sure, Deep Genomics still has a ways to go in preliminary animal work to ensure safety and non-human primate as well as biodistribution before they can move into clinical testing. But the fact that its AI system was able to go from target identification to declaring a winner in 18 months, said CEO Brendan Frey, is a game-changer.
Frey founded Deep Genomics in Toronto in 2014, a couple years after more well-known players such as Atomwise, BenevolentAI and Recursion popped up, based on a decade of research on how AI can help scientists understand genetic diseases. While other platforms have tended to zero in on one part of the puzzle — Atomwise is focused on accelerating small molecule screening, Recursion relies on cell imaging, and insilico uses AI to modify existing drugs — its tech “does the whole thing.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,000+ biopharma pros reading Endpoints daily — and it's free.